This would explain why the delay. Selling off 51% MGC Derma share and still have a contract to supply CBD would be a brilliant idea. R&D and Marketing derma is very expensive and time consuming. The formula works and therefore worth quite a fortune in the right hands. MGC Pharmaceuticals is only one of a few laboratories that have a state of the art GMP facility and with the Malta deal signed it would be best to put all of MGC reserves into MM Research & Development.
How I foresee success in this game is MM is non life threatening unlike most other treatments and remedies.
MGC Pharmaceuticals needs to become the community that most people are seek for advice. I am happy to be part of this story.
The future for Derma?, page-10
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.065(39.4%) |
Mkt cap ! $11.13M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 23.0¢ | 17.5¢ | $97.37K | 451.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 6921 | 5 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| RGT (ASX) Chart |